These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 10458540)

  • 1. Impaired T and NK cell response of bone marrow and peripheral blood stem cell products to interleukin (IL)-2.
    Ozerol I; Ageitos A; Heimann DG; Talmadge JE
    Int J Immunopharmacol; 1999 Aug; 21(8):509-21. PubMed ID: 10458540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural killer and lymphokine-activated killer cell activities from human marrow precursors. II. The effects of IL-3 and IL-4.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Bourhis JH; Gillio A
    J Immunol; 1989 Nov; 143(10):3241-9. PubMed ID: 2809200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunologic phenotype and function in human bone marrow, blood stem cells and umbilical cord blood.
    Mills KC; Gross TG; Varney ML; Heimann DG; Reed EC; Kessinger A; Talmadge JE
    Bone Marrow Transplant; 1996 Jul; 18(1):53-61. PubMed ID: 8831996
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous bone marrow purging by in situ IL-2 activation of endogenous killer cells.
    Margolin KA; Wright C; Forman SJ
    Leukemia; 1997 May; 11(5):723-8. PubMed ID: 9180298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation-induced T cell apoptosis by monocytes from stem cell products.
    Ino K; Ageitos AG; Singh RK; Talmadge JE
    Int Immunopharmacol; 2001 Jul; 1(7):1307-19. PubMed ID: 11460311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies.
    Higuchi CM; Thompson JA; Cox T; Lindgren CG; Buckner CD; Fefer A
    Cancer Res; 1989 Oct; 49(20):5509-13. PubMed ID: 2477142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor.
    Herrera C; García-Pérez MJ; Ramirez R; Martín C; Alvarez MA; Martinez F; Gómez P; García-Castellano JM; Torres A
    Bone Marrow Transplant; 1997 Mar; 19(6):545-51. PubMed ID: 9085733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TNF alpha enhancement of NK and LAK cell functions induced by high-dose IL-2 in human peripheral blood mononuclear cells from patients pretreated with alpha IFN + IL-2.
    Favrot M; Combaret V; Blay JY; Capdeville R; Zhou DC; Clapisson G; Chouaib S; Franks CR; Philip T
    Eur Cytokine Netw; 1990; 1(4):221-7. PubMed ID: 2104243
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isolation of human NK cells and generation of LAK activity.
    Whiteside TL
    Curr Protoc Immunol; 2001 May; Chapter 7():Unit 7.7. PubMed ID: 18432847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherent lymphokine-activated killer cells suppress autologous human normal bone marrow progenitors.
    Miller JS; Verfaillie C; McGlave P
    Blood; 1991 Jun; 77(11):2389-95. PubMed ID: 1903991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NK and LAK activities from human marrow progenitors. I. The effects of interleukin-2 and interleukin-1.
    Keever CA; Pekle K; Gazzola MV; Collins NH; Gillio A
    Cell Immunol; 1990 Mar; 126(1):211-26. PubMed ID: 1689220
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-2-activated cord blood mononuclear cells.
    Derzic S; Slone V; Sender L
    Cytotherapy; 2005; 7(5):408-16. PubMed ID: 16236630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-CD3 + interleukin-2 stimulation of marrow and blood: comparison of proliferation and cytotoxicity.
    Anderson PM; Ochoa AC; Ramsay NK; Hasz D; Weisdorf D
    Blood; 1992 Oct; 80(7):1846-53. PubMed ID: 1391948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interleukin-2 production and response to interleukin-2 by peripheral blood mononuclear cells from patients after bone marrow transplantation: II. Patients receiving soybean lectin-separated and T cell-depleted bone marrow.
    Welte K; Keever CA; Levick J; Bonilla MA; Merluzzi VJ; Mertelsmann R; Evans R; O'Reilly RJ
    Blood; 1987 Nov; 70(5):1595-603. PubMed ID: 3311208
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunologic attributes of cytokine mobilized peripheral blood stem cells and recovery following transplantation.
    Talmadge JE; Reed EC; Kessinger A; Kuszynski CA; Perry GA; Gordy CL; Mills KC; Thomas ML; Pirruccello SJ; Letheby BA; Arneson MA; Jackson JD
    Bone Marrow Transplant; 1996 Jan; 17(1):101-9. PubMed ID: 8673041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; studies of normal polyclonal T cells and T lymphocyte clones derived early after allogenic bone marrow transplantation.
    Bruserud O; Pawelec G
    Cancer Immunol Immunother; 1996 Mar; 42(3):133-40. PubMed ID: 8640841
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fetal BM-derived mesenchymal stem cells promote the expansion of human Th17 cells, but inhibit the production of Th1 cells.
    Guo Z; Zheng C; Chen Z; Gu D; Du W; Ge J; Han Z; Yang R
    Eur J Immunol; 2009 Oct; 39(10):2840-9. PubMed ID: 19637224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological properties of mononuclear cells from blood stem cell harvests following mobilization with erythropoietin + G-CSF in cancer patients.
    Joshi SS; Miller K; Jackson JD; Warkentin P; Kessinger A
    Cytotherapy; 2000; 2(1):15-24. PubMed ID: 12042051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.